Chugai Pharma Reports Phase III Success for Tecentriq & Avastin in Liver Cancer

Chugai Pharma Reports Phase III Success for Tecentriq & Avastin in Liver Cancer

By, Admin 23 May 2025

Tokyo, Japan — Chugai Pharmaceutical Co., Ltd. announced that the Phase III TALENTACE study evaluating Tecentriq (atezolizumab), Avastin (bevacizumab), and on-demand transarterial chemoembolization (TACE) in patients with unresectable hepatocellular carcinoma (HCC) met its primary endpoint with statistically significant and clinically meaningful results.

Study Overview and Outcomes

The TALENTACE study showed a significant improvement in TACE progression-free survival (TACE PFS), the study’s primary endpoint. The overall survival (OS) data remains immature at the time of the first interim analysis, but an additional benefit in progression-free survival (PFS) by RECIST v1.1 was also observed.

Further details will be presented at an upcoming academic congress.

Study Design

The TALENTACE study is a Phase III, open-label, randomized trial designed to evaluate the effectiveness of combining Tecentriq and Avastin with on-demand TACE, versus TACE alone, in systemically untreated patients with unresectable HCC.

Key features:

  • Participants: 342 patients in China and Japan
  • Randomization: 1:1 (Tecentriq + Avastin + TACE vs. TACE alone)
  • Treatment: On-demand TACE
  • Co-primary endpoints: TACE PFS and OS
  • Secondary endpoints: PFS by RECIST v1.1, among others

Significance of Results

This marks the first Phase III study in Asia to demonstrate a TACE PFS benefit from a combination of cancer immunotherapy and targeted therapy with TACE in unresectable hepatocellular carcinoma.

The safety profiles of both Tecentriq and Avastin were consistent with their established safety data and the underlying disease characteristics.

Liver Cancer: An Urgent Global Health Challenge

Liver cancer is the third leading cause of cancer-related deaths worldwide. It is one of the few cancers with increasing mortality rates globally. Each year:

  • More than 500,000 people are diagnosed
  • This equates to one new diagnosis every 50 seconds
  • Survival outlook remains grim:
  • Only 1 in 5 patients are alive five years post-diagnosis
  • Survival rates for advanced liver cancer are significantly lower

Chugai’s Commitment to Innovation

The results of the TALENTACE study reinforce Chugai’s commitment to advancing treatment options for liver cancer through innovative immuno-oncology and targeted therapy combinations. The company continues to explore combination strategies that improve survival outcomes for patients with unmet medical needs.

Optimize Your trial insights with Clival Database.

Are you exhausted from the uncertainty of trial insights pricing? Clival Database ensures the clarity in the midst of the global scenario for clinical trials to you.

Clival Database is one of the best databases that offers an outstanding number of clinical trial data in terms of 50,000+ molecules and from primary regulatory markets as well as new entrants like Indian and Chinese markets.

With Clival, you get accurate positioning of historical sales data, patent database, company profiling, safety & efficacy, and prediction of launch of new innovative molecules helping you to align your research and driving down the cost.

To add value, we further break down our analytics for you so that improving your operational effectiveness; optimizing your clinical trials; and offering you accurate and high-quality data at lowest possible prices becomes possible.

Elevate your trial success rate with the cutting-edge insights from Clival database.

Check it out today and make more informed sourcing decisions! Learn More!